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Abstract  
Incontinentia Pigmenti is an uncommon X-linked genodermatosis, caused by mutations in the NEMO gene. It is a 
systemic disease that involves tissue of ectodermic and mesodermic origin, including cutaneous tissue, teeth, 
eyes and the central nervous system, amongst other organs. The Authors report a rare case of Incontinentia 
Pigmenti in a female newborn. 
Introduction 
 
First described by Bloch in 1926, and 
Sulzberger in 1928, incontinentia pigmenti (IP) is a 
rare X-linked genodermatosis [1, 2], which name is 
related to the histological characteristics of the lesions 
in the third stage (or pigmentary stage) of the disease 
(Tab.1), consisting in the melanin incontinence by 
melanocytes of the basal epidermal layer and by its 
presence in the superficial dermis. 
IP is a systemic disease which involves 
tissues of both ectodermic and mesodermic origin, 
including cutaneous tissue, teeth, eyes and the central 
nervous system, amongst other organs [3]. It is a 
hereditary, X-linked dominant disorder, with high 
penetrance and variable expressivity. It derives by 
mutations in the NEMO/IKKγ/IKBKG gene, located on 
Xq28. NEMO is the essential modulator of NF-kB, a 
transcriptor factor involved in immune and 
inflammatory responses, and in protecting cells from 
tumour necrosis factor-induced apoptosis. Disruption 
of the NEMO gene leads to diminish the NF-kB 
activity and to increase the cells susceptibility to 
apoptosis [4, 5]. Also, inflammatory reactions and 
epidermal eosinophil recruitment, observed in the first 
stages of IP, seems to be important in the 
pathogenesis of the disease. It seems possible that 
the epidermal eosinophil accumulation is related to an 
eosinophil-selective chemokine (eotaxin), produced by 
specific leucocytes (e.g. eosinophils, macrophages, T-
cells) and some structural cells (e.g. endothelial cells, 
fibroblasts and epithelial cells) [6]. 
In male patients, NEMO mutation is linked to 
their embryonic lethality. Female survival is due to the 
lyonization phenomenon (or X chromosome 
inactivation), which occur during early embryogenesis. 
Although its epidemiological data are 
unknown, IP seems to occur in approximately 1 in 
40.000 newborns [7]. About 50% of the IP cases have 
a positive family history of the same disease. The 
disease is predominant in women (F: M = 37:1). Less 
than 3% of cases are described in males. Many of 
them have Klinefelter’s syndrome (47, XXY 
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karyotype), where the second X chromosome seems 
to play an important role in their survival from the 
natural intrauterine death. In the other male cases, 
different genetic mutations have also been described, 
such as hypomorphic alleles or somatic mosaicism for 
the common IKBKG deletion [8, 9]. 
 
 
Case report 
 
A newborn female, 20 days old, affected by a 
diffuse vesciculo-bullous rash showed up to our Clinic 
(Fig. 1). 
The baby was born at term by a spontaneous 
vaginal delivery, which was carried out after 3 hours 
by the membranes rupture. 
The entire pregnancy had taken place 
regularly, without any complication. 
 
Figure 1: Blisters and bullae, on inflammatory ground, localised on 
the trunk, in a linear arrangement which follows the lines of 
Blaschko 
 
 
The patient’s mother was an otherwise 
healthy single woman of 31 years old. She did not 
have previous pregnancies or abortions. During her 
childhood, the woman had suffered from varicella, 
rubeola, parotitis and rubella. 
The woman told us to be affected by epilepsy. 
Her medical treatment, also during the pregnancy, 
consisted of carbamazepine. No other diseases or 
drugs assumptions had been reported. Her familial 
history was insignificant. 
At the mother’s clinical evaluation we did not 
observe any form of cutaneous, nail or hair 
alterations. Maternal serology was negative for VDRL, 
HIV, HBV, HCV. 
Unfortunately, no news about the newborn’s 
father had been reported to us. 
 
Figure 2: Cranial ultrasound shows an immature central nervous 
system, as demonstrated by the bilateral periventricular 
hyperechogenicity of the white substance 
 
During the clinical evaluation, the young 
patient was 48 cm in height, and 2.6 kg of weight, 
which is less than normal. She had normal blood 
pressure, pulse rate and breathing. The 
musculoskeletal system was normal, except for an 
hypoplastic mandible. She did not have ocular or 
abdominal alterations. 
From birth, the newborn suffered from 
seizures. The EEG showed a severely abnormal 
pattern with frequent multi-focal spikes; the head 
ultrasound showed a pattern of immature neurological 
development (Fig. 2). Even if, in a first moment, the 
neurologist thought how seizures could be the result 
of the carbamazepine abstinence, seizures never 
stopped as they were a primary disease.  
During the dermatologic examination, we 
observed clear, tense blister and bullae, on 
inflammatory base. Lesions were localised on the 
extremities and the trunk, in a linear arrangement 
which followed the lines of Blaschko, and seemed to 
be asymptomatic. The Nikolsky test was negative. No 
other lesions were observed in the other cutaneous or 
mucosal areas. 
Hairs were less than normal, wiry and coarse. 
Nails were dystrophic. 
Routine blood testing for inflammation, 
infections and autoimmune diseases were negative, 
except for a peripheral eosinophilia (> 20%). C-
reactive protein and procalcitonin were normal. A 
punch biopsy performed on a lesion showed, in the 
epidermis, a mild acanthosis, foci of eosinophilic 
spongiosis and occasional dyskeratotic keratinocytes. 
In the same time, the dermis showed an infiltrate of 
lymphocytes, eosinophils and nuclear dust derived 
from eosinophilic karyorrhexis (Fig. 3). 
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Figure 3: Histology: The epidermis shows mild acanthosis, foci of 
eosinophilic spongiosis and occasional dyskeratotic keratinocytes. 
The dermis is characterised by an infiltrate of lymphocytes, many 
eosinophils and nuclear dust derived from eosinophilic karyorrhexis 
 
On the basis of the patient’s clinical pattern 
and of the histological examination, we made the 
diagnosis of IP. 
Because of the spontaneous improvement 
and resolution of skin lesions, we prescribed only an 
antibiotic therapy to avoid secondary infections of the 
lesions. 
 
Figure 4: Warty lesions on the right hand 
 
 
Two weeks later, during a follow-up, the 
dermatologic manifestations had been changed, as 
the classic evolution of IP. Linear warty lesions 
appeared on the side of the previous vesicular-bullous 
rash. 
 
 
Discussion 
 
The clinical presentation of IP varies 
considerably, even among the family members of the 
same patient [10]. They range from subtle cutaneous 
and dental involvement to a complex syndrome, 
sometimes deadly. 
Although IP may affect many organs, the 
cutaneous manifestations are the most commonly 
described (l). Typically the cutaneous lesions occur 
along the Blaschko’s lines and evolve through four 
stages (Table 1) [11-13]. 
The first one (bullous stage) is described in 
90% of patients at birth or within the first two weeks of 
life. Sometimes, it may occur in utero and doesn’t 
progress after birth. Clinically, it is characterised by 
clear, tense bullae on inflammatory bases. Lesions 
are mainly described on the extremities (linear 
pattern) and the trunk (linear or circumferential 
pattern). Even if the face is usually spared, scalp 
lesions are quite common. The rash disappears by the 
age of 18 months. Recurrences can seldom be 
observed, also several years after the neonatal 
period, but they are usually shorter and less severe 
than the original eruption. The second stage 
(verrucous one) is characterised by a hypertrophic, 
wart-like rash, with the same localisation of initial 
lesions. Usually, stage 2 starts between the second 
and sixth weeks of life and persists for a few months. 
The third stage (hyperpigmentation stage) is the most 
characteristic one. It usually begins at the age six-
twelve months and persists into the adulthood. 
Clinically, it is characterised by brownish linear and 
whorled streaks which follow the Blaschko’s lines. The 
pigmentation ranges in colour from blue-grey or slate 
to brown. The bizarre splashed or Chinese figure 
distribution is diagnostic. Linear or macular 
telangiectasia may also be described. The last stage 
(fourth stage or atretic one) is described only in 14 % 
patients. Clinically, it is characterised by hypo 
pigmentary and atrophic lesions, in the same areas of 
the previous hyperpigmentation. 
Table 1: Stages of incontinentia pigmenti 
STAGE 
CLINICALCHARACTE
RISTICS 
HISTOLOGIC FEATURES 
STAGE 1 – 
BULLOUS STAGE 
Clear, tense bullae 
and vesicles on 
inflammatory bases. 
Eosinophilic spongiosis, intraepidermal 
vesicles. Inflammation of the dermis, with a 
cellular, infiltrate, including numerous 
eosinophils. 
STAGE 2 - 
VERRUCOUS 
STAGE 
Hypertrophic, wart-like 
rash. 
Dyskeratotic keratinocytes, hyperkeratosis, 
acanthosis and papillomatosis. 
Macrophages laden with melanin may be 
present in the upper dermis. Possible 
signs of epidermal and dermal 
inflammation (epidermal spongiosis, 
cellular infiltrate including numerous 
eosinophils).  
STAGE 3 - 
HYPERPIGMENTATI
ON STAGE  
Brownish linear and 
whorled streaks. 
Melanin incontinence by melanocytes in 
the basal epidermal layer and its presence 
in the superficial dermis. 
STAGE 4 - ATRETIC 
STAGE  
Hypopigmentary and 
atrophic lesions. 
Epidermal atrophy and decreased, normal 
or small melanocytes. Skin appendages 
may be absent.  
 
 
In realty, the onset and duration of each stage 
vary among individuals, and not all individuals 
experience all four stages. Stage 1 and three are 
more commonly observed than stage 2 and 4. Some 
patients may show additional cutaneous 
manifestations such as palmoplantar hyperhidrosis, 
port wine stain, abnormalities of mammary tissue, hair 
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(e.g. alopecia, woolly hair) and nails alterations (e.g. 
onycho- dystrophy, onychogryphosis, pitting, yellow 
discoloration, subungual and periungual keratotic 
tumours) [14,15]. Extracutaneous manifestations may 
also be described. 
Among these, the dental abnormalities (e.g. 
delayed dentition, partial anodontia, hypodontia, 
abnormally shaped teeth) are the most commonly 
reported, occurring in more than 80% of all patients 
[16,17]. 
Ocular defects occur in about 40% of all the 
cases. They include strabismus, cataract, conjunctival 
pigmentosa uveitis, optic nerve atrophy, retinal 
vascular abnormalities, blue sclera, exudative 
chorioretinitis, retinal glioma [18]. 
About 25% of patients have neurological 
disorders, like seizures, spastic or paralytic 
quadriplegia, hemiparesis, cerebral atrophy, 
microcephaly and encephalopathy [19, 20]. The 
incidence of mental retardation is about 25-35%. 
Other extracutaneous manifestations include 
abnormalities of the musculoskeletal system (e.g. 
hemivertebra, hemiatrophy, syndactyly, congenital 
dislocation of the hip, club foot, dwarfism, scoliosis, 
supernumerary ribs), and of the cardiovascular one 
(e.g. atrial septal defects, acyanotic tetralogy of Fallot, 
ventricular endomyocardial fibrosis, tricuspid 
insufficiency, primary pulmonary hypertension) [21]. 
Also, immunologic abnormalities are common 
in IP. They include functional abnormalities of 
neutrophils and lymphocytes and defects in 
polymorphonuclear chemotaxis. Eosinophilia up to 
50% in the peripheral blood is common in the first 
inflammatory stage of IP. 
Unfortunately, to date, no strict diagnostic 
criteria for IP exist. The diagnosis is mainly clinical, 
and it is based on recognition of the typical cutaneous 
lesions. The presence of dental, hair, nails and ocular 
alterations support the diagnosis. Peripheral 
eosinophilia is a suggestive sign in the earlier 
diagnosis. Eventually, a family history of X-linked 
inheritance or a history of multiple miscarriages may 
also support the hypothetic diagnosis. 
The diagnosis may be confirmed only with the 
histological examination of a skin biopsy, and 
molecular genetic test (NEMO mutation). 
In conclusion, because IP is a systemic 
disorder, a multidisciplinary approach to the patients is 
crucial. A complete neurologic examination is 
recommended for all IP infants. 
Regular visits to a paediatric ophthalmologist 
are essential during the first year of life. Laser 
photocoagulation and vascular endothelial growth 
factor inhibitor seem to be good treatments for retinal 
vascular abnormalities [22]. 
Concerning teeth, a radiologic evaluation and 
dental intervention by the age of two years is an 
appropriate therapeutic approach. 
The dermatological management in the 
newborn period is aimed at reducing the risk of 
infection of blisters using antibiotics and hygienic 
preventive measures. Spontaneous improvement and 
resolution of skin lesions is general the rule. Topical 
and systemic steroids may be prescribed to limit the 
rash of the first two stages [23]. The use of laser 
therapies to treat the hyperpigmented lesions of 
should be discouraged because it has been reported 
to trigger an extensive vesicular-bullous eruption [24]. 
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